Housing Watch Web Search

Search results

1. Results From The WOW.Com Content Network

2. Biden administration says Medicare negotiated price discounts ...

   www.aol.com/news/biden-administration-says...

   The list price of Merck's diabetes drug Januvia will be slashed to $113 for a 30-day supply from $527 as of 2023. Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer, will cost $231 for ...

3. Medicare to save $6B in 2026 from the first ever Part D ... - AOL

   www.aol.com/medicare-save-6b-2026-first...

   The blood thinner Eliquis is a top seller for Bristol Myers Squibb. CMS Medicare Part D data shows the government spent $15 billion in 2022 on the drug out of a total of $46.4 billion spent on ...

4. Factbox-Top Medicare drugs headed for price cuts - AOL

   www.aol.com/news/factbox-top-medicare-drugs...

   Jardiance. Boehringer Ingelheim and Eli Lilly's Jardiance is used to treat type-2 diabetes, heart failure and chronic kidney disease. It cost Medicare $7 billion for 1.6 million patients in the ...

5. Medicare announces lower prices on 10 common, high-cost drugs

   www.aol.com/news/first-time-medicare-cuts-prices...

   Here are the negotiated prices for the drugs, based on a 30-day supply: Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price. Xarelto, a ...

6. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Apixaban. Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [ 6][ 7][ 8] Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a ...

7. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Discovery and development of direct Xa inhibitors. Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States ...